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                         INTRODUCTION
Total pelvic exenteration is a radical procedure defined as the complete resection of the 
pelvic viscera and its draining lymphatic system. Ever since Brunschwig published his 
initial experience in 1948 about sixty years ago, the procedure has undergone a major 
evolution from being a desperate experimental procedure to a well established surgical 
procedure with curative intent for selected patients.
In an era of multimodal treatment and organ preservation, exenteration still maintains an 
important place in the armamentarium against advanced pelvic malignancy. The rationale 
for such an ultra-radical procedure is based on the observation by Eugene M Bricker, a 
pioneer in pelvic exenteration, along with pathologist Lauren Ackerman, radiotherapist 
Theodore  Eberhart  and Dr.Juan del  Regato  that  certain  cancers  of  the  pelvic  viscera 
possessed a propensity for remaining confined to the pelvic organs for a long time before 
they metastasize.
The classic examples are the cancers arising from the uterine cervix, vagina, vulva and 
rectosigmoid. Ovarian, prostate and to a lesser extent bladder and endometrial cancers 
most often spread beyond pelvis by the time adjacent viscera are involved.
Eugene M Bricker performed his first total  exenteration on August 8, 1940. Bricker’s 
patient was a 32 year old female with persistent carcinoma of cervix. The development of 
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ileal  conduit  by Bricker in 1950 for urinary diversion was a major advance in pelvic 
surgery. 
Pelvic exenteration was reported by Brunschwig in 1948 as an especially radical surgical 
treatment  for  advanced  and  recurrent  cervical  cancer.  It  was  described  as  “the  most 
radical surgical attack so far described for pelvic cancer” and at the time had an operative 
mortality rate of 23%. In all cases, the ureters were transplanted to the colon proximal to 
a colostomy – the so called wet colostomy.
Cancers arising in the pelvis are often treated with multimodality therapies,  including 
surgical  resection  and  radiation.  When  these  cancers  recur,  many  may  be  locally 
advanced but  still  limited  to  the pelvis;  however,  prior  treatment  with  high  doses  of 
radiation  makes  limited  surgical  resection  a  difficult  undertaking  fraught  with 
complications. Furthermore, the response of tumors to chemotherapy within a previously 
radiated field is extremely poor. In some instances, the only opportunity for cure may lie 
in complete resection. 
Pelvic exenteration is a salvage procedure performed for centrally recurrent gynecologic 
cancers. To a greater or lesser degree, the procedure involves en bloc resection of all 
pelvic  structures,  including  the  uterus,  cervix,  vagina,  bladder,  and  rectum.  Most 
candidates  for  this  procedure  have  a  diagnosis  of  recurrent  cervical  cancer  that  has 
previously been treated with surgery and radiation or radiation  alone.  In some cases, 
patients  with  recurrent  uterine,  vulvar,  or  vaginal  cancers  may  benefit  from  pelvic 
exenteration. In general, patients with ovarian cancer are not candidates because of the 
distant pattern of spread associated with ovarian cancers.
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Pelvic  exenteration  continues  to  be  the  only  curative  option  in  certain  patients  with 
centrally  recurrent  cervical,  vaginal,  or  vulvar  cancers.  Since  Brunschwig's  time, 
improvements  in  critical  care,  antibiotics,  hyperalimentation,  and  thromboembolism 
prophylaxis, accompanied by similar advances in surgical technique, including the use of 
stapling devices, separate urinary conduits, and pelvic reconstruction, have improved the 
morbidity  and  mortality  rates  associated  with  the  procedure.  Currently,  operative 
mortality rates are 3-5%, the major perioperative complication rate is 30-44%, and the 
overall 5-year survival rate in patients who successfully undergo the procedure is 20-
50%. 
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                                           AIM
The study aims to analyze  the various indications,  preoperative evaluation,  technique, 
morbidity, mortality and outcome of pelvic exenterations done at the surgical oncology 
department  of  Government  Royapettah hospital    and  to  compare  the  results  with 
similar international series to evaluate the role of exenterative pelvic surgery in today’s 
practice.
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                         LITERATURE REVIEW
APPLIED ANATOMY
PELVIC SIDEWALLS
The sidewall of pelvis is formed by the hip bone, clad with obturator internus and its  
fascia. The obturator internus muscle arises from margins of obturator foramen and the 
obturator membrane. The origin extends posteriorly as high as pelvic brim and across the 
flat surface of the ischium to the margin of greater sciatic notch. On the ischial tuberosity, 
the origin extends down to the falciform ridge. 
From this  wide origin  the  muscle  fibers  converge  fan-wise  towards  the lesser  sciatic 
notch and makes a right angled bend around the lesser sciatic notch to enter the gluteal 
region.  As  the  muscle  emerges  into  the  gluteal  region,  it  is  reinforced  by additional 
muscle fibers from the lesser sciatic notch. These are the superior and inferior gamelli. 
They blend with the tendon of obturator internus to get inserted into the medial surface of 
greater trochanter. The muscle is covered with a strong membrane, the obturator fascia. 
This is attached to bone at the margins of the muscle and fuses below with the falciform 
process of the sacrotuberous ligament on the ischial tuberosity.  The tendinous arch of 
levator ani slopes across the obturator internus fascia. The pelvic cavity is above this line 
and the ischioanal fossa is below it. Obturator nerve and vessels pass through a gap in the 
superior aspect of the obturator internus muscle
.
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PELVIC FLOOR
The pelvic floor consists of pelvic diaphragm through which the urethra and anal canal in 
both sexes and vagina in females pass.
The muscles of the pelvic floor are levator ani and coccygeus. They arise in continuity 
from the body of pubis, obturator fascia and spine of ischium to get inserted into the 
coccyx and postanal plate.
Levator ani consists of two parts, iliococcygeus and pubococcygeus. The anterior fibers 
of  pubococcygeus  arising  from  the  body  of  pubis,  swing  more  medially  and  more 
inferiorly around the anorectal junction to join with fibres of the opposite side and the 
anal sphincter. This part of the muscle is called puborectalis  and forms a sling which 
holds the anorectal junction angled forwards. The most medial fibres of pubococcygeus 
forms the levator  prostate in males  and pubovaginalis  in females.   The iliococcygeus 
arises  from the  tendinous  arch  of  the  obturator  fascia  and ischium to  insert  into  the 
coccyx. Although the iliococcygeus does not arise from ilium, its name derives from its 
former origin on the iliac bone near pelvic brim. This is still the site of origin in most 
mammals.  In man the origin has descended down the sidewall  of pelvis bringing the 
tendinous arch with it.
The postanal plate where the levator ani gets inserted is a musculotendinous structure 
between the anal canal and coccyx on which the terminal rectum sits. It consists of the 
presacral  fascia,  the  tendinous  plate  of  pubococcygeus,  the  muscular  raphe  of 
iliococcygeus and posterior parts of puborectalis and the external anal sphincter.
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Coccygeus is best thought of as ischiococcygeus as it arises from the ischial spine and 
gets inserted into the side of coccyx and lowest piece of sacrum.
PELVIC FASCIA
Consists of parietal and visceral layers. The parietal pelvic fascia is a strong membrane 
on the pelvic surface of obturator internus. It fuses with periosteum at the upper margin 
of  obturator  internus  and at  the  medial  margins  of  the  anterior  sacral  foramina.  The 
visceral pelvic fascia consists mainly of loose areolar tissue around the pelvic viscera. It 
is condensed around neurovascular bundles supplying these viscera to form ligaments 
such as the lateral cervical ligament, Waldeyers fascia behind the rectum, pubovesical 
and puboprostatic ligaments.
PELVIC VESSELS
Pelvic walls and viscera are supplied by internal iliac artery and drain into tributaries of 
internal iliac veins. Arteries and veins lie within the parietal pelvic fascia. The common 
iliac artery bifurcates at the pelvic brim opposite the sacroiliac joint. Internal iliac artery 
divides into a short posterior and a longer anterior division. The posterior division has 
three branches that supply the parietal wall. These are the iliolumbar, lateral sacral, and 
the superior gluteal arteries. The anterior division has nine branches. Three associated 
with the bladder are the superior vesical which is the first branch, obliterated umbilical 
artery which  is  the  continuation  of  superior  vesical,  and the  inferior  vesical  arteries. 
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Three other visceral branches are the middle rectal, uterine and vaginal arteries. Three 
parietal branches are the inferior gluteal, obturator and the internal pudendal arteries.
INTERNAL ILIAC VEINS
Begins above the greater sciatic notch by the confluence of gluteal veins with others that 
accompany the branches of internal iliac artery.  It joins the external iliac vein on the 
medial surface of psoas major to form the common iliac vein. Apart from the tributaries 
that  correspond to arteries,  the  internal  iliac  vein receives  tributaries  from the  rectal, 
vesical, prostatic,  uterine,  and vaginal venous plexuses. The presence of these venous 
plexus can cause severe haemorrhage if injured. The internal iliac vein communicates 
with the vertebral venous plexus through the lateral sacral veins. There are no valves in 
the pelvic veins. Sudden increase in abdominal pressure can drive blood up into vertebral 
plexus to the posterior intercostal veins and by azygos veins into the superior vena cava 
bypassing the diaphragm. By this way, secondary carcinomatous deposits may enter the 
vertebrae from primary growth in any of the pelvic viscera.
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PELVIC NERVES
Obturator nerve (L2, 3, 4)
The obturator nerve is a branch of the lumbar plexus formed within the substance of 
psoas major. It is the nerve of the adductor compartment of thigh. The obturator artery 
and vein converge to the obturator foramen, in which the nerve lies highest against the 
pubis with the artery and vein beneath it in that order.
Sacral plexus
A part of L4 and all of L5 form the lumbosacral trunk. It descends to join the upper four 
sacral nerves in the formation of the sacral plexus.
Nervi erigentes
It is the parasympathetic pelvic splanchnic nerve arising from S2,3,4. The nerve causes 
erection.
Sacral sympathetic trunks
The sympathetic trunks cross the pelvic brim behind the common iliac vessels and run 
into the concavity of the sacrum. 
Inferior hypogastric plexus
The inferior hypogastric plexus is an autonomic plexus on the sidewall of the pelvis on 
each side.
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INDICATIONS FOR PELVIC EXENTERATION
Pelvic  exenteration  is  primarily  indicated  for  centrally  recurrent  cervical  cancers  in 
patients who have received definitive radiation therapy. The procedure is appropriate in 
patients who meet criteria for any recurrent pelvic tumor if a chance of cure exists with 
the procedure. 
CERVIX
The extensive use of screening examinations and cervical cytologic studies has made it 
possible for most cervical cancers to be detected at an early stage. In a certain number of 
cases, however diagnosis does not occur until the disease is widespread throughout the 
pelvis, representing a daunting treatment challenge. Because of the anatomic features of 
the pelvis and the location of cervical cancer, the urinary system and the rectum are often 
involved. When the cancer persists, or recurs in the pelvis, despite adequate radiation 
therapy, exenterative surgery is often necessary to achieve local control of the disease. 
1/3rd of patients with invasive carcinoma of the cervix have residual or recurrent disease, 
and central recurrence develops in abut 25% of them.
Approximately  30%  of  cervical  cancer  patients  will  ultimately  fail  after  definitive 
treatment.  Regardless  of  treatment  modalities,  more  than  75%  of  recurrence  occurs 
within 3 yrs from diagnosis. The reported 5 year survival rates of patients with treatment 
failure  are  between 3.2% and 13%. Concurrent  chemoradiation  achieves  significantly 
better  outcome than radiation  alone in patients  with recurrences  after  primary radical 
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hysterectomy. Isolated paraaortic lymph node metastases and local recurrence confined to 
cervix were associated with better outcome in failure after definitive radiotherapy. When 
definitive  radiotherapy  or  surgery  plus  adjuvant  radiotherapy  has  failed,  pelvic 
exenteration is usually necessary for those who had central relapse with clear pelvic side 
wall  and  free  of  distant  metastases.  For  patients  who  have  recurrence  involving  the 
irradiated pelvic wall,  pelvic  exenteration is  usually not an option for curative intent. 
Intraoperative  radiotherapy  (IORT),  combined  operative  radiotherapeutic  treatment 
(CORT) and laterally  extended endopelvic  resection  (LEER) have been used  in  such 
situations  with  some  success.  Chemotherapy  alone  is  basically  palliative.  Generally 
combination  chemotherapy  could  attain  higher  response  rates  with  no  significant 
improvement in overall survival than CDDP alone.
Early stage IB and IIA cervical cancer can be cured on an average rate of 80% with either 
radical surgery or definitive radiation, yet 30 – 50% of patients with stage IIB to IV will 
ultimately fail. Recurrent cervical carcinoma remains a tough clinical problem. 
Patients with recurrent cervical cancer after primary treatment with surgery and radiation 
or radiation alone are faced with few options because chemotherapy is at best palliative, 
and the 1- and 5-year survival rates are, respectively, 15% and less than 5%.
Treatment  of  recurrent  disease  depends  on  previous  treatment,  site  or  extent  of 
recurrence, disease free interval and patient’s performance status. According to present 
consensus, patients after  surgical  therapy should be treated with chemoirradiation and 
central pelvic relapses following primary or adjuvant radiation should undergo surgery. 
Radical hysterectomy may be adequate for small, less than 2 cm lesion, but most patients 
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will need pelvic exenteration when there is no evidence of distant metastases. In all cases 
of tumor involvement of pelvic wall exenteration is abandoned. However novel surgical 
salvage  therapy to  a  selected  subset  of  patients  with  locally  advanced  and recurrent 
cervical carcinoma involving the pelvic wall, including pre irradiated patients for whom 
treatment  with  long  term  survival  prospects  has  been  beyond  the  scope  of  current 
therapeutic options, is performed in the form of laterally extended endopelvic resection 
(LEER). 
Patients  with  recurrent  cervical  cancer  after  radiation  therapy  usually  present  with 
bleeding,  hematuria,  or pelvic  pain.  In some cases,  the first  sign of recurrence is  the 
discovery  of  hydronephrosis  or  abnormal  cytology  on  routine  follow-up.  Before 
proceeding  with  the  surgical  procedure,  confirming  a  recurrence  with  a  pathologic 
specimen obtained by biopsy is essential. In patients who have previously had high doses 
of pelvic radiation, physical examination is notoriously unreliable and bleeding and pain 
may be related to radiation changes rather than recurrent disease. The clinical triad of leg 
edema, ureteral obstruction, and leg pain is almost pathognomonic for disease extending 
to the pelvic sidewall and is generally considered a contraindication to surgery. 
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RECTOSIGMOID
Pelvic  exenteration  has  been  done  chiefly  for  treatment  of  advanced  rectosigmoid 
primary disease with varying results. Approximately 10% of patients with rectal cancer 
present with advanced disease that is technically unresectable at the time of diagnosis. 
These patients are usually treated with preoperative radiation in an attempt to shrink their  
tumors  sufficiently  to  permit  standard  abdominoperineal  resection.  It  appears  that 
preoperative radiation can produce a measurable decrease in tumor size but is insufficient 
to control residual disease at  the site of tumor fixation.  For patients with tumors  that 
remain technically unresectable after radiation,  the outlook is even more dismal;  their 
median survival period is 6 to 18 months, with a 5 year survival rate of less than 5%. 
However, pelvic exenteration has a cure rate of 30 – 41%. About 30 – 50% of all patients  
who have primary resection for rectosigmoid cancer have a local recurrence. In 15%, the 
recurrence is found only in the pelvis; there is no evidence of distant metastases. The 
major challenge of pelvic recurrence is tumor fixation to the sacrum or pelvic sidewall, 
which requires extended pelvic exenteration called as composite pelvic exenteration.
For  primary  rectal  cancer,  the  consensus  is  that,  high-risk,  locally  advanced  tumors 
should  be  treated  first  with  chemoradiation  and  exenteration  reserved  as  a  salvage 
procedure. 
VAGINA, VULVA, ENDOMETRUM AND OVARY
Vaginal carcinoma represents the second most common gynecologic lesion treated with 
exenteration. Squamous cell carcinoma accounts for most cases. The proximity of vaginal 
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cancer to the bladder and rectal wall makes these structures especially frequent sites of 
involvement. 
Pelvic exenteration is useful for treating advanced or recurrent squamous carcinoma of 
the vulva when the disease extends to  the urethra,  vagina,  or anus.  The exenteration 
should include an en bloc resection of the vulva with bilateral inguinal lymphadenopathy. 
The use of pelvic exenteration for locally advanced and recurrent ovarian cancer was 
described in an early report by Barber and Brunschwig. The results were not favorable.
BLADDER AND PROSTATE
Rarely carcinoma of the urinary bladder is too extensive for radical cystectomy and may 
require anterior or total pelvic exenteration. Advanced prostate carcinoma has also been 
treated by pelvic exenteration but is probably better managed by radiation or hormonal 
therapy.
RARE TUMOURS OF PELVIC ORGANS
In general sarcomas of the female genital  tract are not appropriate for radical surgery 
because of their tendency toward early metastatic spread by the hematogenous route. 
EVALUATION
As early as 1950, Bricker stated that “if we are unable to leave a patient in a functional 
state compatible with a comfortable existence, we are not morally justified in performing 
this operation”
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Case selection is paramount to success. Early identification of recurrence is associated 
with better chances of resectability. Post-therapy evaluation consists of clinical history, 
physical examination,  pap smear, and serum tumor markers: squamous cell  carcinoma 
antigen(SCC-Ag)  and  CEA  for  squamous  cell  carcinoma;  CA125  and  CEA  for 
adenocarcinoma; and imaging studies.
A  good  physical  examination  must  include  local  and  distant  nodal  regions  because 
supraclavicular  lymph  node  metastases  especially  in  locally  advanced  uterine  cervix 
cancers are not rare. The importance of pelvic examination under anesthesia (EUA) in the 
evaluation  of  resectability  cannot  be  overemphasized.  Although  tumor  adherence  to 
limited  portions  of  the  pelvic  bone  structure  is  not  a  contraindication  to  resection, 
extensive  areas  of  tumor  fixation  is  especially  in  the  lower  pelvis.  Examination  of 
anaesthetized patient allows a careful examination of the rectum and pelvic organs which 
is often limited by pain or discomfort in an awake patient. Examination under anesthesia 
permits a free exchange of views regarding the level and extent of tumor fixation to the 
pelvis as well as invasion into adjacent organs. Also, teaching of fellows, residents, and 
medical students may be conducted without discomfort and embarrassment to the patient.
Progressive  leg  edema  and  back  pain  are  signs  of  parietal  pelvic  wall  involvement 
beyond resectability. Apparent neural involvement such as sciatic nerve impairment is a 
warning sign of extrapelvic tumor involvement. However, these neural signs may be the 
result of previous radiotherapy or chemotherapy or both and thus must be corroborated 
by adequate imaging studies.
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Urinary  tract  obstruction  is  a  relative  contraindication  for  pelvic  exenteration.  The 
ureteric obstruction occurring at the ureterovesical junction is often 20resectable because 
of its central location. Upper pelvic ureteric obstruction where the ureters travel in close 
proximity  to  the  common  iliac  vessels  and  the  pelvic  sidewall  is  more  likely  to  be 
associated with unresectable disease.
The first step in the approach to treating a patient with a biopsy-proven central recurrence 
is  an  exhaustive  search  for  distant  metastatic  disease  and  evaluation  for  comorbid 
conditions.  The initial  surgical  exploration  involves  a  further  search for disseminated 
disease  and  necessitates  a  complete  assessment  of  intraperitoneal  and  retroperitoneal 
areas that would preclude proceeding with exenteration. This task can be accomplished 
by laparoscopy in selected patients. 
LAB STUDIES
• Preoperative laboratory evaluations should include the following:
o CBC count
o Comprehensive metabolic panel
o Coagulation studies
o Type and cross match for blood products
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• Because most patients have received prior treatment, including pelvic radiation 
therapy, an increased likelihood exists of preoperative anemia and, occasionally, 
neutropenia.  A large  number  of  patients  also  have  poor  nutritional  status  and 
electrolyte abnormalities.
• Other testing depends on the existence of other comorbid conditions in individual 
patients.
IMAGING STUDIES
The purpose of performing preoperative imaging studies is to rule out distant metastases, 
to  establish  resectability  or  in  the  case  of  suspected  persistent  disease,  to  attempt  to 
differentiate  between fibrosis  and cancer  recurrence.  Image  directed  biopsies  may be 
ultimately required in cases in which tumor recurrence is neither clinically visible nor 
palpable and therefore not within the reach of a transperineal, transvaginal, or transrectal 
needle core biopsy.  When histologic proof of recurrent  malignancy is  unavailable,  or 
when biopsies are negative for cancer, short term follow up with imaging studies may be 
prudent.
The mainstay of imaging for preoperative assessment of operability is CT scanning of the 
chest, abdomen and pelvis which can identify multiple visceral metastases that are one 
contraindication to exenteration for cure. A potential exception to this contraindication is 
patients with recurrent rectal cancer and 21resectable pulmonary or hepatic metastases.
A word of caution about pelvic exenteration for palliation is necessary. Although several 
publications attempt to justify this operation in the name of palliative care, patients who 
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are incurable by pelvic exenteration should not as a rule be subjected to such a morbid 
procedure. However some important exceptions in which palliative exenteration may be 
advisable include
1. Young and good risk operative candidates who have limited tumor burden
2. Unresectable  distant  disease  along  with  symptomatic  pelvic  recurrence 
that is amenable to complete resection.
3. Patients  with  infected  pelvic  advanced  malignant  disease  which  is 
unresponsive to percutaneous drainage or antibiotics.
4. Fistulas  and  obstruction  that  can  be  relieved  by  exenterative  pelvic 
surgery. 
5. Patients  with  resectable  pelvic  malignant  disease  who have transfusion 
dependent  tumor  bleeding  and  uncontrolled  pain  of  central  or  visceral 
origin but not pelvic parietal pain.
ENDORECTAL ULTRASONOGRAPHY 
Endorectal  ultrasonography  has  become  an  essential  component  of  the  pretreatment 
evaluation  of  transrectal  tumor  invasion  with  an  accuracy of  over  90%.  It  is  not  as 
reliable as a determinant of the extent of disease in the case of recurrent pelvic cancer. 
When exenteration is being considered as a primary form of treatment, MRI, PET and 
even  pelvic  EUA  are  more  diagnostic  than  EUS.  By  the  time  the  rectal  cancer 
necessitates exenterative surgery, knowing the degree of transrectal invasion is beyond 
the value of ultrasonography.
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MRI 
MRI for primary and recurrent pelvic cancer has been studied extensively. Although it 
does not replace CT imaging, MRI improves the visualization of the relationship between 
the advancing edge of the tumor and pelvic fascial planes and muscles. MRI is also useful 
in 23assessing resectability, differentiating fibrosis from tumor invasion and adds further 
anatomic detail to CT in upto40%. MRI has shown a sensitivity of 97% and a specificity 
of 98% compared with 70% and 85% for CT. 
PET
PET scan can reliably detect distant metastatic disease undiscovered by CT scan. Also 
PET has been more accurate than CT in detecting locally recurrent rectal cancer changing 
clinical management in 10 to 61% of patients with recurrent rectal cancer. 
Combining pelvic CT and MRI imaging also is useful in predicting the likelihood of a 
complete resection, especially in cases with pelvic sidewall tumor involvement. 
• The use of imaging studies in evaluating a patient for pelvic exenteration depends 
on the initial assessment of tumor size and location.
• Most patients need a CT scan of the abdomen and pelvis and a chest radiograph. 
Other imaging studies may be used as needed for evaluation of potential areas 
suspicious for metastatic involvement.
o Chest radiograph or CT scan
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o CT scans of abdomen and pelvis
o MRI to evaluate musculoskeletal involvement
o Liver ultrasonography to evaluate for metastatic disease
o Bone scan to evaluate for metastatic disease
o Positron  emission  tomography  (PET)  scanning:  PET scanning  remains 
investigational in the evaluation of cervical cancer but may be very useful 
in excluding small areas of distant metastatic disease.
Other Tests: 
• Psychosocial assessments of patient’s ability to adequately manage postoperative 
physical and psychological issues
• Assessment of comorbid conditions
Psycho-social counseling
The mental condition of the patient should be thoroughly investigated before exenterative 
surgery is considered. The patient should be fully informed about the benefits, objectives 
and risk of the procedure and must demonstrate an understanding and acceptance of all 
possible consequences. Emotional stability and a positive attitude are essential. 
Diagnostic Procedures: 
• Biopsy confirmation of recurrent cancer
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Histologic Findings:  Most cervical cancers are squamous cell carcinomas, though the 
incidence  of  adenocarcinoma  of  the  cervix  is  rising.  Rare  histologic  types  are 
occasionally encountered and include adenosarcomas, uterine sarcomas, and cervical or 
vulvar melanomas.
CONTRAINDICATIONS
Absolute  contraindications  include  peritoneal  metastasis,  metastasis  to  retroperitoneal 
nodes and skip metastasis to bowel. Spread to an adjacent area of small bowel does not 
preclude  exenteration  if  the  peritoneal  cytologic  study  yields  negative  results.  Skip 
metastases  to  the  bowel  however  is  an  absolute  contraindication.  Relative 
contraindications include direct tumor invasion of adherent bowel loops and hydroureter 
or hydronephrosis. 
Determination of the extent of resection is based on sidewall involvement, infralevator 
versus supralevator, and anterior versus posterior versus total exenteration.
 Absolute Contraindications Relative Contraindications
Distant metastases Age over 70 years
Peritoneal carcinomatosis Low pelvic ureteric obstruction
Circumferential pelvic involvement Periosteal tumor fixation
Proximal pelvic ureteric obstruction Moderate co morbidity
Sciatic nerve pain Severe malnutrition
Tumor fixation with bony invasion Non axial recurrence
Progressive leg edema Short disease free interval
Major comorbid conditions Multiple lymph node metastases
Para-aortic nodes 
Mentally ill patients
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 SURGERY
Preoperative details: 
Preparation 
An antibiotic and a mechanical bowel preparation are administered on the day prior to 
surgery. The stoma sites are marked on the skin before surgery. The ideal location for an 
ileostomy  and  colostomy  should  be  marked  by  an  enterostomal  therapist  before  the 
patient goes to the operating room. These sites are generally located halfway between the 
umbilicus and anterior superior iliac spines and must be situated so that there is a ring of 
normal  skin  around the  stoma large  enough to  accommodate  the  ostomy appliances. 
Because previously irradiated skin can get ulcerated or necrosed in the presence of stoma 
or appliance, the radiation ports that were used should be avoided. 
Prophylactic  antibiotics  are  administered  in  the  operating  room,  and  pneumatic  calf 
compression units are placed on the legs prior to the anesthetic induction. Prepare and 
drape  the  potential  operative  field,  including  the  entire  abdomen,  perineum,  vagina, 
rectum, and thighs. 
Position 
The patient  is  positioned supine,  with the  lower extremities  maximally abducted  and 
resting either straight in long-leg traction units, as described by Spratt et al (ski position) 
or with hips fully flexed in the dorsal lithotomy position with knees flexed at 90 degrees 
in leg holders. 
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The procedure  is  typically  performed  with  the  patient  in  the  lithotomy position.  The 
patient’s  legs  are  carefully  placed  in  Allen  or  other  supported  stirrups.  The  correct 
positioning places the weight on the feet and includes padding to ensure protection from 
neurologic injury and to prevent compartment syndrome. 
The tip of the coccyx must extend beyond the end of the folded table. The sacrum must 
be well padded to prevent pressure necrosis and to promote exposure of the posterior 
perineum.  If  a sacral  resection or hemipelvectomy in combination  with a total  pelvic 
exenteration is anticipated, a change to lateral decubitus position may be necessary.
With the patient under general anesthesia, the surgeon should perform a final bimanual 
pelvic examination to reacquaint himself with the tumor’s relationship to adjacent viscera 
or pelvic side wall. In women, obliteration of the vulva is achieved with a continuous 
suture from just above the clitoris to the postanal region. In patients with middle or high 
lesions,  the  labia  majora  can  be  preserved for  perineal  closure.  The patient’s  skin  is 
prepared  from  the  breasts  to  the  knees  with  a  thorough  perineal  and  vaginal  scrub 
included.
Central venous line: 
Adequate vascular access must be available in order to ensure that rapid fluid and blood 
product resuscitation can be instituted if needed. Vascular access also allows invasive 
cardiovascular monitoring as indicated. 
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Intraoperative details: 
Exploration
Through a low midline incision extending from 2 cm above the umbilicus to the pubic 
symphysis,  the  abdomen and pelvis  are  thoroughly explored.  If  the upper  end of the 
incision extends further into the epigastrium, packing of intestines becomes difficult and 
if  the  lower  end  of  the  incision  does  not  expose  the  edge  of  pubic  symphysis, 
mobilization of the pelvic viscera is difficult. The liver, peritoneal and bowel surfaces, 
aortic and pelvic nodal groups, and pelvic sidewall are carefully evaluated.
Biopsies of any suspicious sites and nodes are obtained and examined by frozen section. 
A formal paraaortic lymph node dissection provides no prognostic benefit. Distant and 
peritoneal metastases are absolute contraindications to exenteration. The obturator fossa 
and the region lateral  to  the external  iliac  vessels  are  explored to  determine  whether 
extension beyond the psoas muscle has occurred. In some circumstances like sarcoma, 
resection and reconstruction of the involved external iliac vessels may be justified. Major 
vessel invasion by squamous cell carcinoma and adenocarcinoma, however, is regarded 
as a contraindication to exenteration because cures are rare.
The final  determinant  of  resectability  is  the  exploration  of  the  extraperitoneal  pelvic 
spaces  and  sidewall  structures  and  the  peripheral  attachments  of  the  cardinal  and 
uterosacral ligaments. The peritoneum from the sacral promontory along the brim of the 
pelvis to the bladder is opened. This is done first on the side where the tumor is closest to 
the sidewall. Another exploratory maneuver that is often helpful in defining tumor extent 
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is mobilization of the urinary bladder from the symphysis pubis and the rectum from the 
anterior surface of sacrum. These actions permit better assessment of the mobility and 
lateral  extent  of the tumor  and may allow determination  that  the lesion is  inoperable 
before transaction of the ureters, colon and the visceral blood supply.
Exenteration  is  aborted  in  significant  proportion  of  candidates  who have reasons  for 
aborting the procedure that include peritoneal disease, nodal metastases and so forth.  
Controversy exists  regarding whether  to proceed in  the presence of  nodal  metastasis, 
which reduces the survival rate to 5%, or direct tumor invasion of any adherent loop of 
sigmoid  colon  or  small  bowel.  The  issue  of  sidewall  involvement  is  important  in 
determining 29resectability because the goal is to achieve negative surgical margins. In 
some centers, the availability of intraoperative radiation therapy (IORT) allows resection 
with close margins, but grossly positive margins confer an extremely poor prognosis. The 
process  of  dissecting  open  avascular  spaces  allows  for  further  determination  of 
resectability with adequate margins. 
The pararectal, paravesical, and Retzius spaces are developed under direct visualization, 
and the cardinal ligaments are isolated by this method. The pelvic retroperitoneal spaces 
are  opened,  and the  ureters  and internal  and external  iliac  vessels  are  identified  and 
tagged as necessary. This allows identification of pelvic nodal metastasis, dissection of 
the ureters, and visualization of vessels, which may require ligation to control or prevent 
excessive bleeding.
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When a total  pelvic  exenteration  is  to be performed,  the sigmoid  colon is  divided to 
maintain the specimen in the center of the pelvis. In operations for rectum, the inferior 
mesenteric artery is divided at its origin to ensure an adequate lymphadenectomy. The 
small  intestine and the stapled proximal end of the divided colon are packed into the 
upper abdomen. The caecum is partly mobilized and held cephalad with the folded edge 
of  laparotomy  gauze  under  the  blade  of  a  Deaever’s  retractor.  A  5  –  10  degree 
Trendelenberg position is helpful and should be requested before intestinal packing is 
done. If too much packing or force is applied, physiologic changes may occur as a result 
of an abnormally elevated diaphragm, occlusion of the hepatic veins or IVC, impaired 
blood flow to the intestines, or compression of the aorta or vena cava by the retractors. 
Careful positioning of packs and retractors is more important than great force in attaining 
necessary exposure.
Only one important somatic nerve, the obturator nerve, actually lies on the visceral side 
of  the  parietal  layer  of  the  pelvic  fascia.  This  fascia  can  be  incised  over  the  nerve., 
thereby  separating  it  from  the  central  pelvic  tissue  without  exposing  the  neoplasm. 
Occasionally the proximity of the tumor necessitates the sacrifice of this nerve to ensure 
an adequate margin around the lesion. Unilateral  division of the nerve results in little 
disability, but the disability may be considerable when the division is bilateral.
Before proceeding with lateral dissection, it is helpful to mobilize the rectum from the 
presacral space. In patients with rectal tumors, it is best to divide the mesorectum sharply, 
avoiding blunt dissection that may leave behind residual disease or perforate the tumor 
bearing rectal segment. When the posterior rectal wall is not involved, blunt dissection to 
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the tip of the coccyx is permissible. It is important to stay anterior to the presacral veins 
to avoid troublesome bleeding. Similarly anterior blunt dissection of the prevesical space 
is  simple  and  useful  as  long  as  the  periurethral  venous  plexus  near  the  urogenital 
diaphragm is not disturbed.
With the lateral dissection, the rectum and bladder are mobilized. There are no lymph 
nodes lateral  to the genitofemoral nerve lying on the psoas muscle.  Thus, the parietal 
layer  of  the  endopelvic  fascia  is  divided  medial  to  the  genitofemoral  nerve,  thereby 
preserving  the  nerve.  The  parietal  endopelvic  fascia  is  then  reflected  medially.  It  is 
contiguous with the vascular sheath of the common and external iliac vessels. The sheath 
is dissected off these vessels. The testicular or ovarian vessels and round ligament are 
divided. 
The ureters are transected 3 – 4 cm distal to the crossing of the external iliac artery. It is  
preferable to divide the ureters later in the procedure after the lateral dissection has been 
completed bilaterally. This is done for two reasons: It generally represents a “point of no 
return” and it allows continuous measurement of urinary output and avoids leakage of 
urine into the operative field for a longer time.
The pelvic fascia is reflected from the psoas muscle to the lateral side of the external iliac 
artery.  The fascia is reflected from the dorsal surface of these vessels to the obturator 
internus muscle and arcus tendineus. The obturator nerve is identified and protected by 
reflecting it laterally.  The obturator vein and artery are identified passing through the 
obturator foramen and are divided. The visceral branches of the internal iliac vessels are 
ligated and divided. If the tumor is close to the hypogastric vessels, they are also ligated. 
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Care must be taken to avoid the superior gluteal artery that originates on the deep or 
lateral surface of internal iliac artery near its origin.
The  bladder  attachments  are  transected  next.  The  peritoneal  incision  that  was  made 
lateral  to the external  iliac vessels and medial  to the genitofemoral  nerve is extended 
toward the internal abdominal ring and onto the lower edge of the midline abdominal 
incision. The areolar tissue in the prevesical space is dissected away from the pelvic side 
of the pubis, staying adjacent to the pubic peritoneum.
The rest of the lateral pelvic dissection depends on the condition of the perivenous tissues 
and identification of the lumbosacral trunk. This trunk composed of the fourth and fifth 
lumbar nerve roots, is situated dorsal and lateral to the obturator nerve lying adjacent to 
the caudal fibers of the obturator internus.  Once it has been identified, the other sacral 
roots should be avoided by continuing the dissection medially and downward. 
After the remaining vascular structures have been transected, the extent of the dissection 
along the pelvic  surface of levator  ani muscle  is  determined by assessment  of lateral 
extent of neoplasm. When the levator ani has been circumferentially demonstrated, the 
rectum mobilized to the coccyx, and the bladder mobilized to the periurethral region, the 
perineal dissection begins.
Perineal dissection
For total exenteration in women, the perineal incision extends from the base of clitoris to 
behind the anus, just lateral to the labia minora or majora. The amount of skin sacrificed 
32
is determined by the type and proximity of the neoplasm. For cancers extending low into 
the vagina, vulva, or perineum, a wider area of skin should be removed. 
In men, the incision extends from the base of the scrotum to the coccygeal area. The 
urethra is ligated and divided. The urethra is brought out through a subscrotal tunnel to 
maintain the continuity of the en bloc dissection. In women the urethra is removed en 
bloc with the specimen.
After the subcutaneous tissues are divided, the ischium is identified by palpation, and the 
perineal fascia overlying the ischiorectal fat is incised medial to the ischium.  The levator 
ani fibers are detached from the pelvic insertions. The levator ani is grasped between the 
index and middle fingers and transected on both sides of pelvis about a finger breadth 
from its origin on the arcus tendineus. Finally, the retro pubic periosteal insertions are 
divided and the specimen is removed through the perineum.
The empty pelvic cavity is checked for hemostasis.  There are generally two principal 
bleeding  points:  The transverse  perineal  artery  and the  inferior  rectal  artery,  both  of 
which are branches from the internal pudendal artery in the pudendal canal. If possible 
the dissection should not enter this canal. The arteries are rarely a source of difficulty. If 
the veins are torn, they may bleed persistently, particularly in the following areas: the pre 
sacral veins, the obturator vein which can retract into the obturator foramen, between the 
sacral  nerve  roots  from  the  retracted  branches  of  the  internal  iliac  vein,  along  the 
pudendal canal, and behind the symphysis pubis.
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Occasionally there may be persistent hemorrhage from the deep pelvic vessels that can be 
controlled only by gauze packing.  Early recognition of the need for packing prevents 
additional serious blood loss. If packing must be done, a rubber or plastic sheet (2x3ft) is 
folded to lie within the pelvis like a sack whose opening is at the perineal wound. Inside 
the sack, gauze pads are tightly packed to fill the pelvis completely and exert lateral and 
posterior  pressure  on it.  Although such packing is  rarely necessary nowadays,  it  can 
provide life saving hemorrhage control. Packs are left till clot retraction occurs.
The perineal  wound is  closed  in  two layers.  The colostomy is  then  created.  Urinary 
diversion is done.
The  empty  pelvis  is  frequently  the  source  of  considerable  morbidity,  especially  in 
patients who have had radiation therapy. Procedures for filling in the empty pelvic cavity 
are now an important component of reconstruction in patients undergoing exenteration. 
Sometimes an omental flap fills most of the pelvic cavity. Other methods that can be used 
include placement of absorbable or permanent mesh at the pelvic inlet or of pedicled 
myocutaneous flaps or free flaps using microvascular reconstruction. 
LAPAROSCOPY
Staging laparoscopy for abdominopelvic malignancy before laparotomy has a definitive 
place  in  the  modern  surgical  armamentarium.  The  most  compelling  reason  to  use 
laparoscopy is because the finding of  miliary peritoneal implantation or a cytological 
smear  showing  malignant  cells  in  peritoneal  fluid  or  lavage  neither  of  which  is 
recognizable  in  imaging  studies  constitutes  a  categorical  contraindication  to  pelvic 
34
exenteration  for  cure.  Staging  laparoscopy  is  thus  advised  in  all  patients  before 
exenteration in whom it is technically feasible.
From a technical view point, there is no impediment to an oncologically sound en bloc 
dissection of the entire pelvic viscera and its associated lymphatics. In fact, laparoscopy 
provides better visualization of deep pelvic recesses than open surgery using deep pelvic 
retractors. At present, laparoscopic pelvic exenteration for locally advanced pelvic cancer 
cannot be advocated as the preferred operative approach.
Experiences with pelvic exenteration have shown that tactile sensation plays an important 
role  in  guiding the operation,  especially  when portions  of  the pelvic  viscera  may be 
preserved. The advancing edge of the tumor can be best ascertained by palpation of the 
viscera as dissection progresses. Although the gross margin required for Ro resection is 
generally 2 cm, the failure to anticipate the required tissue resection margins can make a 
potentially curative resection into a palliative one. 
Although staging laparoscopy has been used primarily for upper abdominal malignancy, 
the use of this procedure has been reported by Kohler and colleagues in patients with 
gynecological  malignancies  who are being  considered  for  pelvic  exenteration.  In  this 
study 50% of patients were ineligible for pelvic exenteration on the basis of laparoscopic 
findings
TYPES OF PELVIC EXENTERATIONS 
1. Total pelvic exenteration
35
2. Modified pelvic exenteration 
3. Extended pelvic exenteration
TOTAL PELVIC EXENTERATION
Total pelvic exenteration is the removal of the uterus, cervix and vagina along with the 
urinary bladder and urethra anteriorly and the rectum and anal canal posteriorly.
MODIFIED PELVIC EXENTERATION
There are four main types of modified pelvic exenterations. They are 1. Anterior pelvic 
exenteration 2. Posterior pelvic exenteration 3. Anterior exenteration with proctectomy 
and 4. Supralevator pelvic exenteration.
ANTERIOR PELVIC EXENTERATION
In an anterior pelvic exenteration, the bladder, lower part of ureters, reproductive organs, 
draining  lymph  nodes,  and  pelvic  peritoneum  are  removed.  An  en  bloc  resection 
maintains  the  rectum  in  situ  because  the  posterior  vaginal  wall  and  uterus  serve  as 
margins for resection. Urinary diversion is done as in standard pelvic exenteration.
This  type  of  exenteration  is  done for  carcinoma of  bladder  involving  the  cervix  and 
vagina,  primary  cervical  or  vaginal  carcinomas  with  extension  into  the  bladder  and 
extensive vulvar carcinomas involving both the periurethral and vaginal regions.
POSTERIOR PELVIC EXENTERATION
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In women, this procedure includes resection of the rectogenital organs, an end colostomy, 
and preservation  of  the bladder  and ureters.  This  operation  is  suitable  for  low rectal 
carcinomas  not  amenable  to  low  anterior  resection  with  a  coloanal  anastamosis  and 
confirmed invasion of the posterior vaginal wall sufficiently extensive to require near 
total vaginectomy and en bloc resection of the uterus.
ANTERIOR EXENTERATION WITH PROCTECTOMY
This procedure is indicated in men with bladder tumors extending to the middle or upper 
rectum,  prostatic  carcinomas  or  sarcomas  involving  a  portion  of  the  rectal  wall.  In 
women the procedure is appropriate for tumors of the bladder or internal genitalia with 
limited  extension  into the middle  or upper  rectum.  Following resection,  rectosigmoid 
anastamosis is done and urinary diversion is done as usual using ileal conduit.
SUPRALEVATOR EXENTERATION
In  this  procedure,  the  pelvic  organs  are  excised  at  the  level  of  the  levator  muscles, 
preserving the lowest portion of rectum and anus as well as the urogenital diaphragm. All 
coloanal  anastamosis  should  be  protected  by  either  a  diverting  colostomy  or  a  loop 
ileostomy.  The  splenic  flexure  should  be  mobilized  and  the  inferior  mesenteric  vein 
divided at the lower edge of pancreas to provide sufficient mobility for a tension free 
coloanal anastamosis. 
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EXTENDED PELVIC EXENTERATION
This procedure involves removal of a part of the bony pelvis also. This is also called as 
composite pelvic exenteration.    
LATERALLY EXTENDED ENDOPELVIC RESECTION (LEER)
Laterally extended endopelvic resection includes the internal iliac vessel system, 
endopelvic part of the obturator internus muscle, coccygeus, iliococcygeus, and 
pubococcygeus muscles into the exenteration specimen. Complications, disease 
free and overall survival rates and postoperative quality of life scores of patients 
with sidewall disease are comparable to those with central disease treated with  
standard exenteration.
RECONSTRUCTION
Rectal anastamosis 
The decision to perform an end-sigmoid colostomy or a low rectal anastamosis is based 
on the level  of  the resection,  the  length  of  the rectal  stump,  and the  extent  of  other 
concomitant procedures. A low rectal anastamosis can usually be accomplished using the 
circular  end-to-end  anastamotic  stapling  device.  Reports  have  evaluated  the 
complications associated with a rectal anastamosis at the time of pelvic exenteration, and 
the overall incidence of anastomotic leaks or fistula formation is 30-50%. A protective 
colostomy or  omental  wrap  has  not  been  found to  have  a  significant  impact  on  the 
incidence of successful healing by some studies. Recent data suggest that a higher leak 
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rate occurs in patients undergoing concomitant procedures such as IORT and continent 
urinary diversions. 
Urinary diversion 
Several  options  exist  for  urinary  diversion,  and  the  choice  of  continent  versus 
noncontinent urinary diversion is based on assessment of the patient’s ability to care for a 
continent pouch and availability of right colon and ileum with the ileocecal valve. The 
best option for noncontinent diversion is an ileal urinary conduit in which the ureters are 
implanted in an isoperistaltic manner into a segment of small bowel, one end of which is 
brought  out  as  a  cutaneous stoma.  Other  options  are  to  use the transverse colon,  the 
jejunum  or  the  sigmoid  colon.  The  advantages  of  ileal  conduit  are  the  ease  of 
reconstruction, improved stomal preservations, greater flexibility, greater length to reach 
the abdominal wall even in obese individuals, adequate blood supply, and a convenient 
stomal location on the right lower quadrant. It is also associated with low incidence of 
infection  and  metabolic  abnormalities,  thus  preserving  the  renal  function.  The  main 
disadvantage is that bowel segments have been previously irradiated, thereby increasing 
the complications of ureteral stricture, fistulas and stomal necrosis. If significant radiation 
injury to the small bowel is observed at surgery, other options should be considered.
Transverse colon conduits have gained considerable popularity. The advantages are that it 
can be used in previously irradiated patients as it rarely lies in the field of irradiation, the 
bowel  anastamosis  also  lies  outside  the  irradiated  pelvis,  thereby  having  less 
complications compared to ileal conduits. Colon conduits are less likely to have stomal 
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complications.  It  can be used in  obese patients  with short  ureters.  The stoma can be 
placed anywhere on the anterior abdominal wall. 
Jejunal conduit is rarely used as the complication rates are higher. The most common 
complication is the electrolyte imbalance, known as the Jejunal syndrome. Similarly the 
sigmoid  colon  conduits  are  also  not  used  nowadays.  The  main  disadvantage  is  that 
marked radiation changes are seen in previously irradiated patients. 
The continent  pouch uses the right colon as a low-pressure reservoir,  with the ileum, 
ileocecal valve, or appendix specially configured to create the continence mechanism. A 
variety of continent pouches with small variations have been described. Kock was the 
first  to  introduce  the low pressure reservoir  created  by detubularisation  of  the  bowel 
using a segment of ileum. The most widely used ileocolonic continent reservoirs include 
the Miami pouch, Indiana pouch, and the Mainz pouch.
Complications  associated  with  both  continent  and  noncontinent  urinary  diversions  in 
women who are gynecologic oncology patients have been reported by several authors. A 
continent urinary diversion allows the patient to have only a single ostomy bag, or none 
at all, and it can be successfully accomplished in patients with gynecologic cancer. Early 
complication rates range from 12-53%, and long-term complication rates from 33-37%. 
The reoperation rate is 6-8%. 
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Pelvic reconstruction
The complication  of pelvic  exenteration  can be very troublesome due to  the residual 
pelvic defect responsible for a high incidence of postoperative small intestinal obstruction 
and fistula formation. Most patients who undergo pelvic exenteration will benefit from 
placement of well vascularised flaps in the residual pelvic space to block entry of bowel, 
revascularize  the  irradiated  pelvic  cavity  walls,  decrease  the  occurrence  of  pelvic 
infections, fistulae, and chronically open perineal wounds.
Omentum is commonly used to fill the pelvic cavity. Among myocutaneous flaps, rectus 
abdominis flaps are used for the vaginal and pelvic reconstruction. It is done at the time 
of radical pelvic surgery. The flap is designed and elevated after removal of the pelvic 
organs. It is important to make sure that the inferior epigastric vascular pedicle was not 
divided during the pelvic resection. If it was, the contralateral rectus abdominis is used. If 
both the vessels were divided, a gracilis reconstruction is done.
Vaginal reconstruction 
Several methods for vaginal and pelvic reconstruction have been described. An omental 
flap can be accomplished, generally with minimal morbidity, and serves to carpet the raw 
exposed surfaces of the exenterated pelvis. Myocutaneous grafts, including rectus and 
gracilis muscle flaps, can be brought into the pelvis and perineum to create pelvic support 
and a neovagina. Split-thickness skin grafts have also been used to create neovagina. The 
gracilis V-Y advancement flap is widely used for vulvar reconstruction and resurfacing of 
perineum.
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RECENT ADVANCES
Controversy continues regarding the appropriate selection of patients for exenteration and 
the  use  of  IORT,  combined  operative  radiotherapy  (CORT),  preexenteration 
chemotherapy,  concomitant  continent  urinary  diversion,  and  low  rectal  anastamosis 
avoiding ostomies.
IORT
Intraoperative radiotherapy in its broadest sense refers to the delivery of radiation at the 
time of an operation. There are two methods of such delivery of radiation. One is the 
Intraoperative electron radiotherapy using external beam radiotherapy and the other is the 
HDR – IORT using high dose rate brachytherapy.  Both these IORT methods evolved 
with  the  attempt  to  achieve  higher  effective  doses  of  radiation  while  dose-limiting 
structures are surgically displaced. 
IOERT
For  patients  who  have  recurrences  involving  the  pelvic  wall,  pelvic  exenteration  is 
conventionally not an option for curative intent. However Monge-Martinez et al reported 
outcomes in 67 patients treated with intraoperative electron beam therapy (IOERT). The 
10 years in field control rates were 92.8% in primary and 46.4% in recurrent tumors. 10 
years overall survival rates were 58% and 14% respectively.
Appropriateness of IORT should be determined by the surgeon and radiation oncologist 
in the setting of a joint preoperative consultation whenever feasible. The dose  and energy 
of  IOERT depend on the amount of residual disease after maximum resection and on the 
external beam RT already given before surgery. The IOERT dose is 10 – 12.5 Gy for 
microscopic residual disease and 15 – 20 Gy for gross residual disease. Doses upto 25 – 
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30 Gy can be given for those patients who have not received any radiation. The biologic 
effectiveness of single dose of IOERT is considered equivalent to 1.5 to 2.5 times the 
same total  dose of fractionated EBRT. Peripheral  nerve is the principal  dose limiting 
normal tissue for IOERT in the pelvis and retroperitoneum.  Hence all patients are given 
an informed consent about possible nerve related side effects. 
Because  of  the  physical  limitations  of  the  electron  beam and  finite  diameter  of  the 
electron beam applicator,  IOERT may be unsuitable for treatment of sites deep in the 
inferior  pelvis,  subpubic  location  and  some  areas  of  lateral  pelvic  side  wall.  The 
disadvantages of IOERT are
1. Expensive to have a dedicated linear accelerator in the operating room.
2. Requires transporting of the anaesthetized patient to the radiotherapy room 
if a dedicated machine is not available.
3. Dosimetry is similar to EBRT and does not allow dose escalation within 
the target volume or surface.
HDR – IORT becomes the modality of choice for these difficult situations. This method 
of using HDR – IORT after surgical resection of disease at pelvic sidewalls is called 
Combined Operative Radiotherapy (CORT). 
CORT
Whereas 25 to 50% of selected patients who relapse centrally in irradiated pelvis can be 
salvaged  by  exenteration,  post  irradiation  recurrence  infiltrating  the  pelvic  sidewall 
generally has been fatal. 
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Combined operative radiotherapy has been developed to treat recurrent gynaecological 
malignancies  infiltrating  the  pelvic  wall  unilaterally.  The  surgical  part  consists  of  i) 
staging laparotomy/ lymphadenectomy, ii) maximum tumor resection at pelvic wall with 
only a microscopic margin(R1) preserving the bony pelvis and the neurovascular support 
of  the  leg,  and  exenteration  of  infiltrated  central  pelvic  organs,  iii)  implantation  of 
guiding tubes on the residual tumor/tumor bed on the pelvic wall, iv) pelvic wall plasty 
with muscles,  musculocutaneous  and omental  flaps  for  modulation  of  the  therapeutic 
index for a second high dose radiation of the pelvic wall, v) operative reconstruction of 
bowel, bladder and perineovulvovaginal functions. Radiation is performed as interstitial 
high dose rate brachytherapy through the implanted tubes. 
CORT has been evaluated in the University of Mainz medical school, Mainz, Germany 
between April 1989 and December 1994. A total of 48 patients were treated. At a median 
follow up of 33 months, the 5 year survival was 44%. Overall local control rate wsas 68% 
nom patient  died as a  consequence of  the treatment.  Age of the patient,  state  of the 
resection at the pelvic wall (R1 vs. R2) and recurrent tumor size independently influenced 
tumor progression after CORT in this series.
CORT appears to be a feasible innovative treatment with long term survival potential and 
acceptable quality of life for selected patients with post irradiation gynecological tumor 
recurrence infiltrating the pelvic wall. 
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Advantages of HDR – IORT are that hypoxia and sublethal damage repair are less of an 
issue because of longer treatment time. Higher central dose can be achieved and there is 
less risk to normal tissue. However the disadvantages are inability to do homogenous 
implants due to adjacent vessels and curved pelvic surface and inability to displace dose 
limiting organs for prolonged interval. 
Potential Differences between IOERT and HDR – IORT
S.No Factors IOERT HDR-IORT
1. Actual treatment time 2- 4 minutes 5 – 30 minutes
2. Total procedure time 30 – 45 minutes 45 – 120 minutes
3. Treatment sites Accessible locations All areas 
4. Surface dose Lower Higher 
5. Dose at depth of 2 cm Higher Lower 
6. Dosimetric homogeneity <10% variation >100% variation 
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MATERIALS AND METHODS
All the patients who had undergone pelvic exenteration surgery in the surgical oncology 
Department of Government Royapettah hospital were taken up for analysis. Total number 
of patients  who had undergone this  procedure was 39.  Out  of  these,  20 patients  had 
undergone surgery in the period between September 2005 and May 2008. The remaining 
19 patients had undergone surgery before this period from 1996 to 2005. The records of 
these patients were analyzed retrospectively and the patients were followed up regularly.
The  pre  operative  evaluation  of  these  patients  consisted  of  a  thorough  clinical 
examination, routine blood and urine examination, chest radiography, Ultrasonography of 
Abdomen and Pelvis, CT scan of Abdomen and Pelvis and Examination under anesthesia 
(EUA). Selected patients were additionally evaluated with MRI and Cystoscopy. All the 
patients underwent a biopsy and pathological documentation of the disease was done. All 
the patients were counseled about the outcome and the stoma care and the relatives were 
explained  about  the  procedure.  Written  informed  consent  was  obtained  from all  the 
patients.
Patients who were not willing for surgery or those with contraindications for surgery and 
those considered medically unfit for surgery were excluded from the study. Patients who 
underwent laparotomy but had inoperable disease were also not included.
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The various indications,  the types  of exenterations  performed,  types  of reconstruction 
procedures  used,  the  postoperative  complications  and  patterns  of  recurrence  were 
analyzed. All the patients were followed up once a month in the first year after surgery,  
once in two months during the second year, every three months during the third year, 
once in six months upto five years and annually thereafter. During follow up thorough 
clinical  examination  and  annual  ultrasound  abdomen  and  chest  radiography  were 
performed.  Symptomatic  patients were further evaluated with CT scan.  Survival was 
analyzed using Kaplan Meier curve.   Results were compared with international  series 
published in the literature.
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OBSERVATION & ANALYSIS
Totally 39 patients who had undergone pelvic exenteration in the Department of Surgical 
Oncology at Government Royapettah Hospital were taken up for analysis. Out of these, 
35 were females and 4 were males. The majority of our patients were females because the 
commonest  indication  for  which  pelvic  exenteration  was  done  in  our  series  was 
carcinoma cervix.
MALE FEMALE
4 35
SEX-WISE DISTRIBUTION
4
35
MALE
FEMALE
Age of the patients ranged from 21 years  to 72 years.  Old age was not considered a 
contraindication  for  pelvic  exenteration  in  our  series.   However,  Age has  often  been 
considered a contraindication to radical exenterative surgery in many reports.  A 1992 
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report from M.D. Anderson cancer centre reviewed the outcome in 63 patients who were 
65 years of age or older and found that their operative mortality was 11% as compared 
with 8.5% in younger patients. The 5 year survival rate cited for older patients was 46% 
and 45% for younger patients. 
The authors concluded that the morbidity and mortality levels in their elderly patients 
were comparable to those reported in previous studies of younger patients and that the 5 
year  survival  periods were similar  in the two groups,  and age could not therefore be 
considered a contraindication to exenteration.
In our series also, the postoperative morbidity in the elderly age group of above 60 years 
was comparable to that of the younger age group. The average age of our patients was 
47.7 among females and 54.0 among males. Majority of our patients were in the 41 – 50 
age group. Total number of patients above 60 years was 8, with 5 females and 3 males. 
The results in this subgroup were comparable to that of the younger age groups. The age 
wise distribution of patients in our series is as shown below.
AGE GROUP FEMALE MALE
20 – 30 1 1
31 – 40 10 0
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41 – 50 13 0
51 – 60 6 0
61 – 70 4 3
71 – 80 1 0
TOTAL 35 4
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The various indications for pelvic exenteration in our series were for residual or recurrent 
disease in locally advanced pelvic malignancies after radiation and/or chemotherapy. The 
total  number  of  cases  of  carcinoma  cervix  were  18,  carcinoma  rectum  were  11, 
endometrial  carcinoma  were  2,  uterine  sarcoma  was  1,  carcinoma  vagina  were  3, 
carcinoma  anal  canal  were  2,  carcinoma  ovary  was  1  and  carcinoma  of  the  urinary 
bladder was 1.
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Diagnosis  Total Number of cases percentage
Carcinoma Cervix 18 46.1%
Carcinoma  Rectum 11 28.2%
Carcinoma Endometrium 2 5.1%
Carcinoma Vagina 3 7.6%
Sarcoma Uterus 1 2.5%
Carcinoma Anal canal 2 5.1%
Carcinoma Ovary 1 2.5%
Carcinoma Urinary bladder 1 2.5%
Total 39
SITE-WISE DISTRIBUTION
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Carcinoma cervix  was the  most  common disease  in  our  series  and carcinoma of  the 
rectum was  the  second  most  common.  In  a  10  year  review of  the  Memorial  Sloan-
Kettering  cancer  centre,  the  primary  disease  site  and  initial  treatment  in  patients 
undergoing  pelvic  exenteration  for  recurrent  or  persistent  gynecologic  carcinomas  is 
shown in the table below.
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Site No.of patients Surger
y 
Radiation Surgery 
+RT
Surgery +Chemo
Cervix 51 12 35 4 0
Vagina 5 0 5 0 0
Vulva 4 3 1 0 0
Endometrium 2 0 0 1 1
Ovary 2 0 0 0 2
Total 64 15 41 5 3
Various  types  of  exenterations  were  performed  in  our  series.  Of  the  39  patients,  16 
underwent  anterior  pelvic  exenteration,  11  underwent  total  pelvic  exenteration,  8 
underwent  posterior  pelvic  exenteration,  3  underwent  modified  supralevator  pelvic 
exenteration and 1 patient underwent extended pelvic exenteration.
Type of exenteration Number of cases Percentage 
Anterior Pelvic Exenteration 16 41.0%
Posterior Pelvic Exenteration 8 20.5%
Total Pelvic Exenteration 11 28.2%
Extended Pelvic Exenteration 1 2.5%
Modified Supralevator Pelvic Exenteration 3 7.7%
Total Number of cases 39
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 TYPES OF PELVIC EXENTERATION
16
8
11
1
3
Anterior Pelvic Exenteration
Posterior Pelvic Exenteration
Total Pelvic Exenteration
Extended Pelvic Exenteration
Modified Supralevator Pelvic
Exenteration
Revision Urinary Conduit with Transverse colon
ANUSUYA 39 / F
CD NO 95 / 05
PROF RR, GRH
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Previous 
Ileal conduit
Revision with 
Transverse colon conduit
FOLLOW –UP AFTER 3YEARS
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ILEAL CONDUIT AND COLOSTOMY
MODIFIED PELVIC EXENTERATION
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TOTAL PELVIC EXENTERATION
VESICOVAGINAL FISTULA
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ANTERIOR PELVIC EXENTERATION
COMPOSITE PELVIC EXENTERATION
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PELVIC RECONSTRUCTION WITH OMENTUM
For  urinary  and  fecal  diversion,  the  different  methods  used  were  ileal  conduits,  wet 
colostomy  and  double  barrel  colostomy.  Pelvic  floor  reconstruction  was  done  using 
Omentum for most of the cases. For those who underwent anterior pelvic exenteration, 
ileal conduit was the only method of urinary diversion adopted in our series. However for 
one patient the conduit had to be revised and converted into a colonic conduit due to post 
operative  complication.  For  those  who underwent  posterior  pelvic  exenteration,  fecal 
diversion  was  done  through  colostomy  and  for  those  who  underwent  total  pelvic 
exenteration,  urinary  and  fecal  diversion  were  done  through  two  separate  ostomies 
consisting of colostomy and ileal conduit or as a single ostomy through wet colostomy or 
double barrel colostomy. 
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While using double barrel colostomy the distal end of the colon was turned on itself like a 
‘turn bull’ colostomy and the ureters were dunked into the distal segment. The opening 
for urinary diversion was placed above the fecal opening to avoid fecal contamination of 
the urinary tract. 
The ureters were dunked into the ileal conduit or the colon as the case may be instead of 
mucosal anastamosis. A few seromuscular stitches were placed to fix the ureters to the 
bowel segment. This method provided the advantage of avoiding an anastamosis and the 
resultant complications such as anastamotic leak or stenosis. Moreover, the excess ureter 
that hangs inside the bowel segment, even if sloughs off, does not add to the morbidity. 
As  most  of  the  cases  have  received  pelvic  radiation,  the  distal  ureter  that  has 
compromised  blood  supply,  is  more  likely  to  slough  off  and  this  complication  was 
avoided in our series by this dunking method. Another advantage of this technique is that 
in the postoperative period, if a mucus plug obstructs the stoma, the excess hanging distal 
ureters get folded due to back pressure and avoid reflux of urine into the upper urinary 
tract.
The urinary complications were less in the ileal conduit group than the wet colostomy 
group. In the 3 patients who underwent modified supralevator exenteration, sphincters 
were preserved, continuity restored and ostomy avoided. 
Pelvic reconstruction was done using omentum. As almost  all  our patients  underwent 
surgery after irradiation,  this  was an essential  component  of pelvic exenteration.  This 
procedure avoided small bowel complications in our patients. However 3 patients (7.6%) 
developed perineal wound complications. Two patients developed perineal fistula. In one 
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patient  the fistula  was from the ileal  conduit  and she had urine draining through the 
perineal fistula 5 months after the surgery. She underwent revision of the conduit and a 
colonic conduit was used. This patient later developed soft tissue recurrence in the pelvis 
after a disease free interval of 33 months and was given chemotherapy. She is still alive 
with  the  disease.   In  the  second patient,  enterocutaneous  fistula  developed and fecal 
material was draining through the perineal fistula. At laparotomy, she was found to have 
densely plastered bowel loops in the pelvis. Exclusion of the involved bowel segment 
was done and ileostomy done for diversion. This patient died in the postoperative period 
following the second surgery and her disease free interval was 12 months. One patient 
developed perineal  wound dehiscence  and herniation  of  the  small  bowel  through the 
perineal  wound.  This  patient  refused  any  surgical  intervention  and  was  managed 
conservatively. The perineal wound healed well.
The post operative complications observed ranged from minor wound infections to burst 
abdomen in the early postoperative period and bowel obstruction, fistula formation and 
urinary complications in the late period. The complications encountered are as shown 
below.
S.No Complications Number of patients Percentage 
1. Abdominal Wound Infection 19 48.7
2. Perineal Wound Infection 21 53.8
3. Abdominal wound dehiscence 12 30.7
4. Perineal  wound dehiscence 6 15.3
5. Burst abdomen 6 15.3
6. Intestinal obstruction 2 5.1
7. Fistula 2 5.1
8. Urinary tract infection 17 43.5
9. Electrolyte imbalance 5 12.8
10. Reoperations 9 23.0
11. Perioperative mortality 0 0
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12. Recurrences 4 10.2
COMPLICATIONS
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Out  of  the 39 patients,  12 patients  did not  experience  any complication.  The overall 
morbidity was 69.2%. The high complication rate observed in our series is due to the fact 
that majority of these patients were operated after chemotherapy and/or radiotherapy. The 
nutrition status of these patients was also poor and these factors contributed to the poor 
wound healing and the operative complications. However none of our patients died in the 
immediate postoperative period and the perioperative mortality was 0% in our series.
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Reoperations were required for 8 patients (20.5%). Out of these, 6 patients underwent 
relaparotomy and secondary suturing for burst abdomen. All these patients had received 
radiotherapy prior to surgery. 1 patient underwent revision of urinary conduit, 1 patient 
underwent laparotomy and exclusion of the bowel segment for enteroperineal fistula and 
1 patient underwent gluteal advancement flap for wound dehiscence.  This patient had 
undergone extended pelvic exenteration for carcinoma rectum infiltrating the sacrum.
The  high  complication  rate  observed  in  our  series  is  concordant  with  similar  series 
reported.  In  the  literature,  it  is  observed that  the  potential  complications  after  pelvic 
exenteration are numerous and almost every patient develops at least one complication. 
Approximately 40-50% experience a major complication requiring further diagnostic and 
therapeutic procedures. The operative mortality rate is 2-5% in modern series. The major 
early  postoperative  complications  include  blood  loss,  sepsis,  wound  dehiscence,  and 
anastamotic breakdown at the level of the bowel, urinary pouch, or ureteral sites. The rate 
of late complications is lower, but approximately one third of patients experience fistula, 
bowel  obstruction,  ureteral  strictures,  renal  failure,  pyelonephritis,  and chronic  bowel 
obstructions.  Other  complications  include  deep  venous  thrombosis  and  pulmonary 
emboli, flap necrosis, and stomal necrosis.
The  complications  of  urinary  diversion  procedure  include  electrolyte  abnormalities 
leading  to  hyperchloremic  metabolic  acidosis  in  ileal  or  colonic  conduits  and 
hyponatremic  hyperkalemic  metabolic  acidosis  in  jejunal  conduits,  nephrolithiasis, 
nutritional  complications  due  to  removal  of  substantial  length  of  bowel  segment  in 
continent  pouches,  adenocarcinoma  in  40%  of  patients  with  ureterosigmoidostomy, 
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decreased  urinary  output,  urinary  leak,  ureteral  stricture,  urinary  incontinence,  and 
infections.
Orthotopic  urinary  diversions  are  becoming  increasingly  popular.  It  was  initially 
performed successfully in men. It is now being successfully performed in women too. A 
potential  candidate  for an orthotopic neobladder must  have an intact  external  urethral 
sphincter  to  provide  continence  and  allow  conscious  voiding  through  the  urethra. 
Exenterative  procedures  including  the  vulva  eliminate  the  possibility  of  orthotopic 
urinary diversion.
Most of the 30 day mortality , as high as 20% in the 1950’s was caused by postoperative 
septic complications and the impact of radiation enteritis on small intestinal loops caught 
in  the  empty  and  denuded  pelvic  cavity,  resulting  in  frequent  episodes  of  intestinal 
obstruction and fistulas. The contemporary experience with exenterative pelvic surgery 
suggest that morbidity from this operation remains high, whereas operative mortality has 
decreased to less than 5%. Preserving the nutritional  status  of these patients,  modern 
imaging  permitting  non  operative  management  of  intra  abdominal  sepsis,  decreasing 
reoperation rates, which contributed to increased mortality in previous decades.
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Morbidity and mortality of pelvic exenteration 
Series Years No.of patients Morbidity Mortality 
Lopez&Monafo 1993 232 45% 14%
Perlman 1994 77 38% 5%
Hockel et al 1996 48 33% 0%
Goldberg et al 1998 154 47% 14%
Law et al 2000 24 54% 0%
Chen HS et al 2001 50 37% 2%
Wig et al 2002 47 38.29% 13%
Ike et al 2003 45 77.8% 13.3%
Poletto et al 2004 96 15.6% 19.8%
Present Study 2007 39 69.2% 0%
Disease recurrence was noted in 4 patients (10.2%). Out of these, 3 patients (7.7%) had 
local recurrence and 1 patient (2.5%) had distant recurrence.  The median disease free 
interval in those patients who developed local recurrence was 27.3 months. The disease 
free interval in the patient who developed distant recurrence was 14 months. This patient 
developed  lung  metastases  and  received  palliative  chemotherapy.  Recurrence  was 
detected  by  CT  scan  done  for  symptoms  of  lower  abdominal  pain  and  the  distant 
recurrence was detected on routine annual radiograph.
In a recent publication, Stab and colleagues have demonstrated that PET has an accuracy 
of 87% in detecting pelvic  recurrence.  The clinical  value of  FDG-PET  for primary 
staging in cervical cancer seems promising .A few retrospective studies have investigated 
FDG-PET  as  routine  post  treatment  surveillance  or  to  determine   whether   various 
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clinical situation suspicious of recurrence are true recurrences . A study by Rower et al 
has prospectively investigated the role of PET in 27 patents with unexplained elevation of 
SCC- Ag levels [MRI and/or CT normal or inconclusive] .PET findings were positive for 
19  of  them,  of  which  17  were  conformed  to  have  recurrence,  and  such  expedited 
detection  of  recurrent  cervical  cancer  led  to  positive  effects  on  patients  survival.  In 
another  prospective  trial,  the  diagnostic  efficacy  and  benefit  of  PET  restaging  in 
documented  recurrent  cervical  cancer  was  evaluated.  A  total  of  55%  patients  had 
treatment modified due to PET findings. 
There has been no consensus regarding appropriate follow-up schedules. Soisson et al 
investigated  clinical  parameters  in  the  detection  of  recurrent  cervical  carcinoma after 
radical hysterectomy. And they found vaginal cytology had a sensitivity of 13 and 100% 
and pelvic examination 58 and 96%. Vaginal cytology is not cost effective or sensitive. It 
is less useful in post-radiation situations. 
Out  of the 39 patients  in our series,  10 patients  (25.6%) died during follow up. The 
median survival in these patients was 11.4 months. Out of the remaining 29 patients, 3 
patients were lost to follow up and the remaining 26 patients are on regular follow up. 
The  longest  survival  noted  is  144  months  in  a  case  of  carcinoma  rectum  who  had 
undergone posterior pelvic exenteration. 
The median survival observed in our series was 27.2 months.  Site wise analysis showed 
that best outcome was seen in patients with carcinoma rectum. Patients with carcinoma 
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cervix had poorer results compared to rectum. The number of patients in the other sites is 
too low to comment on the outcome. The site-wise median survival is as shown below.
S.No Diagnosis Number of 
Patients 
Median survival
In months
1. Carcinoma cervix 18 18.6
2. Carcinoma rectum 11 43
3. Carcinoma anal canal 2 92
4. Carcinoma Endometrium 2 10
5. Carcinoma vagina 3 10.3
6. Sarcoma uterus 1 11
7. Carcinoma ovary 1 7
8. Carcinoma urinary bladder 1 2
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Apart  from  the  site  of  the  disease,  presence  of  nodal  metastases  also  was  a  poor 
prognostic  indicator.  Similar  difference  in  outcome is  seen in  studies  reported  in  the 
literature. In colorectal cancer, tumor invasion of adjacent viscera is prognostically more 
favorable than tumors confined to bowel wall, with metastasis to lymph nodes. Among 
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86 cases of multivisceral resections for colorectal cancer, more than 80% had histological 
evidence of adjacent organ invasion, but in less than 30% were metastases found in the 
regional lymph nodes. The 5 year survival in this group of patients was 76%, despite the 
locally advanced T stage. Similar findings were reported in a small  group of patients 
treated with total pelvic exenteration for rectal cancer and in another study after resection 
of  portions  of  the  bony  pelvis,  the  so  called  composite  pelvic  exenteration,  was 
performed.
Recurrent endometrial carcinoma has been treated with pelvic exenteration in which the 
disease is limited to the central pelvis. Barber and Brunschwig reported a 5 year survival 
rate of 14.5% after the procedure, a result that is less favorable than that for carcinoma of 
cervix. In the series of Reid et al, however 9 out of 46 patients with sarcoma of vagina, 
cervix or uterus underwent pelvic exenteration with a 5 year survival rate of 55%.
In the series reported by Hopkins and Morley,  4% of all patients with vulvar cancers 
underwent pelvic  exenteration for extension of the disease to the urethra,  base of the 
bladder, anus, or rectum; their 5 year survival was 60% although metastatic disease in 
lymph nodes markedly decreases their life expectancy.
The 5 year survival was calculated using Kaplan Meier method and the estimated 5 year 
survival in our series was 58.7%. This is in concordance with the results published by 
other studies  in the literature.  Reported 5-year  survival  rates after  pelvic  exenteration 
ranged from 23-61%
KAPLAN MEIER CURVE
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The most common site of recurrence is the pelvis. Poor prognostic factors associated with 
recurrence after exenteration include tumor size greater than 3 cm, pelvic  sidewall  or 
resection margin involvement,  nodal metastasis,  and time interval  of less than 1 year 
from  prior  radiation  treatment.  Recent  data  suggest  that  local  failures  after  pelvic 
exenterations are still at an average of 20%. When tumour extent requires a composite 
pelvic exenteration, the recurrence rate increases to approximately 30%, as reported by 
Gonzalez and associates. Unfaourable tumour biology, nonaxial tumour recurrence, poor 
patient  selection,  previous  extensive  surgery,  and  surgical  inexperiences  are  all 
unfavourable prognostic indicators.
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Series Year Primary tumour No.of patients 5-year survival
Hockel et al 1996 Gynaecologic 48 44%
Meterissian et al 1997 Rectum 40 49%
Hida et al 1998 Rectum 50 64%
Law et al 2000 Rectum 24 44%
Zhang et al 2000 Gynaecologic 18 15%
Chen et al 2001 Rectum 50 49%
Poletto et al 2004 Mixed 96 41.9%
Present Study 2007 Mixed 39 58.7%
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                               CONCLUSION
The indolent  behavior  of  certain  pelvic  cancers  is  what  makes  pelvic  exenteration  a 
feasible procedure for the cure of locally advanced neoplasms. Pelvic exenteration today 
must  be  viewed in  the  context  of  a  salvage  operation  aimed  at  a  potential  cure,  not 
primarily as a palliative effort. 
This daunting procedure must  be performed by surgeons experienced in multivisceral 
resections, in an environment in which pelvic reconstruction, patient rehabilitation, and 
interdisciplinary cancer care are provided with the leadership of surgeons who understand 
and embrace multimodal treatment of patients with cancer. Several recent publications 
attest to the increasing use of this procedure internationally.
Our analysis shows that the procedure can be done with acceptable complications and is 
the  only  curative  hope  in  selected  patients.  Though  organ  preservation  and  minimal 
approach surgery is the recent trend in surgical management,  there exists a small  but 
definite place for this procedure in the surgical management of locally advanced pelvic 
tumors who have exhausted all other modalities of treatment.
Though  there  was  no  dedicated  counseling  team or  separate  stoma  therapists  in  our 
hospital,  still  our  analysis  shows  that  more  patients  are  willing  to  understand  the 
magnitude of this surgery and come forward to undergo the surgery. The good five year 
survival seen in our analysis which is in par with the western studies, shows that our 
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patients  can  also  tolerate  this  extensive  surgery despite  differences  in  nutritional  and 
socioeconomic status and lack of good rehabilitation.
However  the  morbidity  in  our  series  was  high  owing  to  multiple  factors.  The  poor 
nutritional  status,  lack  of  personal  hygiene,  previous  irradiation  and  nosocomial 
infections are some of the factors that have contributed to this high complication rate. 
Efforts  to  reduce  these  complications  and  evolving  techniques  to  avoid  stomas  and 
introduction  of  newer techniques  such as  IOERT and CORT would help in applying 
pelvic exenterations to more number of patients.   
Pelvic  exenteration  remains  a  challenging  procedure  with  significant  morbidity.  The 
operation has evolved along with imaging, perioperative care, and adjuvant therapy.
In carefully selected patients, pelvic exenteration provides curative form of treatment and long 
term survival. Improvements in imaging and selection of patients, advancements in radiotherapy 
techniques and good rehabilitation in future will increase the number of patients benefited with 
this procedure.
Pelvic exenteration has retained its place in the armamentarium of surgeons with interest 
in  pelvic  cancer  surgery.  Bricker  said  it  well  in  his  last  contribution  to  the  surgical 
literature  “ordinarily after 40 years, a new operation will  have been discarded or so  
modified and improved that its origin becomes unrecognizable and is forgotten. The fact  
that  there  is  still  a  place  for  the  comparatively  simple  concept  behind  the  early  
operation- and the knowledge that it still serves a useful purpose- is a great boost to my  
ego”. 
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PROFORMA
ROLE OF EXENTERATIVE SURGERY IN LOCALLY ADVANCED
 PELVIC TUMOURS
NAME: ADDRESS:
C.D NO:
AGE:
SEX: M/F
OCUPATION:
PH.NO:
DIAGNOSIS:
PRIMARY/RESIDUAL/RECURRENCE
COMPLAINTS AND DURATION:
ABDOMINAL PAIN: Y/N
ABDOMINAL MASS: Y/N
ABDOMINAL DISTENSION: Y/N
WHITE DISCHARGE: Y/N
VAGINAL BLEEDING: Y/N
POST MENOPAUSAL/POSTCOITAL
URINARY SYMPTOMS: Y/N
FREQUENCY/RETENTION/INCONTINENCE/HAEMATURIA/DYSURIA
ALTERED BOWEL HABITS: Y/N
DIARRHOEA/CONSTIPATION/BLEEDING PR/INCONTINENCE
LOW BACK ACHE: Y/N
:
SWELLING OF FEET: Y/N    R/L/BIL
LOSS OF APPETITE Y/N
LOSS OF WEIGHT: Y/N
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PREVIOUS H/O TREATMENT: Y/N
MONTH AND YEAR OF DIAGNOSIS:
DIAGNOSIS AND STAGE AT THAT TIME:
CERVIX: IA1/IA2/IB1/IB2/IIA/IIB/IIIA/IIIB/IVA/IVB
BLADDER:T     N     M
RECTUM: T     N     M
PROSTATE: T     N     M
UTERUS:IA/IB/IC/IIA/IIB/IIIA/IIIB/IIIC/IVA/IVB
OVARY:IA/IB/IC/IIA/IIB/IIC/IIIA/IIIB/IIIC/IVA/IVB
OTHERS:
HISTOPATHOLOGICAL TYPE:
ADENOCARCINOMA/SQUAMOUS CELLCARCINOMA/SARCOMA/MELANOMA
GRADE:I/II/III
TREATMENT GIVEN:
RADIOTHERAPY:EBRT/BRACHYTHERAPY/BOTH
TOTAL DOSE:
NO.OF FRACTIONS:
INTERVAL BETWEEN EBRT&BRACHY
CHEMOTHERAPY:Y/N
DRUG: CISPLATIN/5FU/ADRIAMYCIN/PACLITAXEL/CARBOPLATIN/OTHERS
NO. OF CYCLES:
PREVIOUS SURGERY:
PANHYSTERECTOMY/ EXTENDED HYSTERECTOMY : TYPEI/II/III/IV/V
ANTERIOR RESECTION/ APR
PARTIAL CYSTECTOMY/RADICAL CYSTECTOMY
RADICAL PROSTATECTOMY
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FAMILY H/O CANCER:Y/N
IF YES, DEGREE OF RELATIONSHIP: 1ST/2ND/3RD 
H/O CANCER IN SPOUSE/SEXUAL PARTNER: Y/N
H/O STD IN SEXUAL PARTNER: Y/N
PREMENOPAUSAL/POSTMENOPAUSAL
SMOKER/NON SMOKER
ALCOHOLIC/ NONALCOHOLIC
VEG/NON VEG
MARITAL STATUS:MARRIED/UNMARRIED
AGE AT SEXUAL ACTIVITY:
NO. OF CHILDREN:
CO-MORBID CONDITIONS:DM/HTN/IHD/COPD/TB
CLINICAL EVALUATION:
PERFORMANCE STATUS(ECOG):I/II/III/IV
BUILD:OBESE/MODERATE/THIN
NUTRITION:WELL/MODERATE/ILL
PAEDAL OEDEMA: Y/N
UNILATERAL/BILATERAL
PITTING/NON PITTING
ASCITES: Y/N
LYMPHADENOPATHY: Y/N
ILIAC/INGUINAL/PARA-AORTIC/SUPRACLAVICULAR
ORGAN INVOLVED:
CERVIX/VAULT:
SIZE OF THE LESION:    <4 CMS    /    > 4 CMS
FORNIX INVOLVEMENT: Y/N
ANTERIOR/POSTERIOR/RT. LATERAL/ LT.LATERAL
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PARAMETRIA:
RIGHT: SUPPLE/NODULAR/THICKENED
LEFT: SUPPLE/NODULAR/THICKENED
MOBILITY: Y/N
SIDE WALLS: Y/N
BLADDER INVOLVEMENT: Y/N
VESICO VAGINAL FISTULA: Y/N
RECTAL INVOLVEMENT: Y/N
RECTO VAGINAL FISTULA: Y/N
VAGINAL INVOLVEMENT: UPPER 1/3 / UPPER 2/3 / LOWER 1/3 /NIL
NODES: ILIAC/INGUINAL/PARA-AORTIC/SUPRACLAVICULAR
RECTUM:
TYPE OF LESION: ULCERATIVE/PROLIFERATIVE
SIZE:     CMS.
DISTANCE FROM ANAL VERGE:      CMS.
SPHINCTER INVOLVEMENT: Y/N
MOBILITY: Y/N
ADJACENT STRUCTURE INVOLVEMENT: Y/N
BLADDER/ UTERUS/URETERS/PROSTATE/SACRUM/SIDE WALLS
NODES: ILIAC/INGUINAL/PARA-AORTIC/SUPRACLAVICULAR
LIVER SECONDARIES: Y/N
BLADDER:
SIZE OF THE LESION:   CMS
SITE:
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ADJACENT STRUCTURE INVOLVEMENT: Y/N
RECTUM/ UTERUS/URETERS/PROSTATE/SACRUM/SIDE WALLS
NODES: ILIAC/INGUINAL/PARA-AORTIC/SUPRACLAVICULAR
LIVER SECONDARIES: Y/N
UTERUS:
SIZE OF THE LESION:    CMS
PARAMETRIA:
RIGHT: SUPPLE/NODULAR/THICKENED
LEFT: SUPPLE/NODULAR/THICKENED
ADJACENT STRUCTURE INVOLVEMENT: Y/N
CERVIX/VAGINA/RECTUM/ BLADDER/URETERS/PROSTATE/SACRUM/SIDE 
WALLS
NODES: ILIAC/INGUINAL/PARA-AORTIC/SUPRACLAVICULAR
INVESTIGATIONS:
HB%                                           BLOOD GROUP:A1/A2/B/A1B/A2B/AB/O       RH: +/-
BLOOD UREA:                         BLOOD SUGAR:                               SR.CREATININE:
CHEST X-RAY: NORMAL/ SECONDARIES
USG ABDOMEN:
ORGAN : CERVIX/BLADDER/RECTUM/PROSTATE/UTERUS/OVARY/OTHERS
SIZE OF THE LESION:
SOLID/CYSTIC/MIXED
ASCITES:Y/N
HYDRONEPHROSIS:R/L/BIL/NO
NODES: ILIAC/INGUINAL
CT SCAN ABDOMEN &PELVIS:
ORGAN: CERVIX/BLADDER/RECTUM/PROSTATE/UTERUS/OVARY/OTHERS
SIZE OF THE LESION:
HYDRONEPHROSIS:R/L/BIL/NO
NODES: ILIAC/INGUINAL/PARA-AORTIC/MESENTERIC
FAT PLANE BETWEEN:
MALE: BLADDER//RECTUM
FEMALE:BLADDER//UTERUS//RECTUM
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CT CHEST:NORMAL/ SECONDARIES
MRI: 
ORGAN: CERVIX/BLADDER/RECTUM/PROSTATE/UTERUS/OVARY/OTHERS
SIZE OF THE LESION:
NODES: ILIAC/INGUINAL/MESENTERIC/PARA-AORTIC
CYSTOSCOPY: NORMAL/DISEASED
SIZE OF THE LESION:
SITE:TRIGONE/LATERAL WALLS/DOME
NO. OF LESIONS:
TYPE OF LESION: ULCERATIVE/PROLIFERATIVE
ASSOCIATED CA.IN SITU:
URETERIC ORIFICE:NORMAL/DILATED/OBSTRUCTED
BIOPSY TAKEN:Y/N
SIGMOIDOSCOPY/COLONOSCOPY:
LESION: Y/N
SIZE OF THE LESION:
TYPE OF THE LESION:ULCERATIVE/PROLIFERATIVE
DISTANCE FROM ANAL VERGE:
PASSAGE OF SCOPE BEYOND THE LESION: Y/N
SYNCHRONOUS LESIONS: Y/N
BIOPSY TAKEN: Y/N
OTHER INVESTIGATIONS IF ANY:
HISTOPATHOLOGY:
SIZE OF TUMOUR:        CMS
TYPE:SQUAMOUS/ADENO/UNDIFFERENTIATED/TRANSITIONAL/SARCOMA/
MELANOMA/OTHERS
GRADE:I/II/III
ORGANS INVOLVED:
CERVIX:ENDO/ECTO
UTERUS:ENDOMETRIUM/INNER ½ MYOMETRIUM/OUTER 
½MYOMETRIUM/ENDO CERVIX/CERVIX STROMAL 
INVASION/SEROSA/ADNEXA/VAGINA/BLADDER MUCOSA/BOWEL MUCOSA
TUBES:
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OVARY:R/L
BLADDER:NON INVASIVE PAPILLARY/IN SITU/SUBEPITHELIAL/INNER ½ 
MUSCULARIS/OUTER ½ MUSCULARIS/BEYOND 
MUSCULARIS/PROSTATE/VAGINA/UTERUS
RECTUM:SUBMUCOSA/MUSCULARIS PROPRIA/PERI RECTAL
SIGMOID: SUBMUCOSA/MUSCULARIS PROPRIA/PERI COLIC
PROSTATE:< ½ OF 1 LOBE/ > ½ OF 1 LOBE/ 
BOTH/EXTRACAPSULAR/SEMINAL VESICLE/BLADDER NECK/EXTERNAL 
SPHINCTER/RECTUM
OTHER STRUCTURES REMOVED IF ANY:
MARGINS:+/-/CLOSE
LYMPHOVASCULAR INVASION: Y/N
NODES:ILIAC/PERIRECTAL/MESENTERIC
NO.OF NODES RESECTED:
NO. NODES POSITIVE:
EXTRACAPSULAR DISEASE: Y/N
CYSTOSCOPIC BIOPSY:+/-
SIGMOIDO/COLONOSCOPIC BIOPSY:+/-
TREATMENT:
PRE-OP:RT/CT/NIL
RADIOTHERAPY: CHEMOTHERAPY:
TOTAL DOSE:                                                                                DRUG USED:
NO.OF FRACTIONS:                                                                NO.OF CYCLES:     
DOSE PER FRACTION:
SURGERY:
INTERVAL BETWEEN PRE-OP TREATMENT AND SURGERY:
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FINDINGS DURING SURGERY:
ASCITES/PERITONEAL DISEASE/PARA-AORTIC NODES/LIVER 
SEC/PARAMETRIUM/SIDE WALLS
FROZEN SECTION : PARA AORTIC NODE:+/-
TYPE OF SURGERY:
EXTENDED HYSTERECTOMY:I/II/III/IV/V
TYPE OF 
EXENTERATION:ANTERIOR/POSTERIOR/TOTAL/EXTENDED/MODIFIED
RADICAL CYSTECTOMY
RADICAL PROSTATECTOMY
ANTERIOR RESECTION
APR
BOWEL RESECTIONS IF ANY:
ANASTAMOSIS:STAPLER/MANUAL
RECONSTRUCTION:
CONTINENT/NON CONTINENT
ILEAL CONDUIT/COLONIC CONDUIT
COLOSTOMY
ILEOSTOMY
RECONSTRUCTION OF VAGINA: Y/N
COMPLICATIONS: Y/N
WOUND INFECTION: Y/N
WOUND DEHISCENCE: Y/N
FISTULAS:ENTERIC/URETERO VAGINAL/VESICO VAGINAL/RECTO 
VAGINAL/RECTO VESICAL
COLOSTOMY: HERNIA/STENOSIS
ILEOSTOMY:STENOSIS Y/N
BOWEL OBSTRUCTION: Y/N
URINARY INFECTION: Y/N
HYDRONEPHROSIS: Y/N
DETERIORATING RENAL FN: Y/N
ELECTROLYTE IMBALANCE: Y/N
PELVIC ABSCESS: Y/N
VAGINAL DISCHARGE: Y/N
THROMBOEMBOLISM: Y/N
UROLITHIASIS: Y/N
DISCHARGED/EXPIRED
81
FOLLOW-UP
                                                                                                          DATE   
PARAMETERS:
                              1’ST 2’ND 3’RD 4’TH
LOCAL RECURRENCE
SOFT TISSUE RECURRENCE
ILIAC NODES
INGUINAL NODES
PARAAORTIC NODES
SUPRACLAVICULAR NODES
ASCITES
LUNG SECONDARIES
RENAL PARAMETER ELEVATION
WEIGHT GAIN IN KGS.
MASTER CHART
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S.
N
o
Name
A
g
e
S
e
x
Diagn
osis
Stag
e
At 
Diag
nosis
Initial
Treatme
nt
Indica
tion 
for
Exent
eratio
n
Type 
of 
exent
eratio
n
Type 
of 
urinar
y/feca
l 
divers
ion
Pelvic 
reconst
ruction
Postop 
compli
cations
recurr
ence
Foll
owu
p 
peri
od 
in 
mon
ths
Sta
tus
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1
Shanmug
avadivu
4
0
F
Ca 
rectum
IIB
Preop 
chemo
residu
e
PPE
colost
omy
oment
um
Nil Nil 137
Ali
ve
2 Suseela
3
0
F
Ca.rect
um
IIIB
Preop 
chemor
adiation
residu
e
PPE
colost
omy
oment
um
Nil Nil 12
Di
ed
3 Sumathi
3
8
F
Ca 
rectum
IIB
Pre op 
chemo
Res PPE
Colost
omy
Nil
Woun
d 
Infecti
on
Nil 62
Ali
ve
4
Patchaim
uthammal
5
0
F
Anal 
canal
III A
Pre op 
chemor
adiation
Res PPE
Colost
omy
Nil Nil Nil 108
Ali
ve
5
Nallamm
al
6
2
F
Rectu
m
III B
Preop 
chemo
Res PPE
Colost
omy
Nil
Woun
d 
Infecti
on
Nil 61
Ali
ve
6
Alagiya 
meenatch
i
4
9
F
Rectu
m
III A
Chemot
herapy
Res PPE
Colost
omy
Oment
um
Nil Nil 6
Ali
ve
7
Mariamm
al
7
2
F
Anal 
canal
III A
Chemor
adiation
Rec PPE
Colost
omy
Oment
um
Woun
d 
Infecti
on
Nil 76
Lo
st 
foll
ow 
up
8
Mariamm
al
3
5
F Cervix I B
Surgery 
+ RT
Rec TPE
Wet 
colost
omy
Oment
um
Woun
d 
Infecti
on + 
wound 
dehisc
ence
Nil 12
Di
ed
9 Sumathi
3
2
F Cervix IIB RT Rec APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
ence
Locor
egiona
l 
recurr
ence
22
Di
ed
10 Alamelu 4 F Cervix IIB RT Rec TPE Wet Oment Woun Nil 36 Lo
84
3
colost
omy
um
d 
Infecti
on+ 
wound 
dehisc
ence
st 
foll
ow 
up
11
Salima 
begum
4
8
F Cervix IIIB
chemor
adiation Res TPE
Wet 
colost
omy
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
ence
Nil 11
Di
ed
12
Balagang
a
4
2
F Cervix IIIB RT Rec APE
Ileal 
condu
it
Oment
um
Nil Nil 10
Di
ed
13
Palaniam
mal
4
5
F Cervix IIIB RT Rec APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on
Nil 27
14
Murugan
adam
2
1
M
Rectu
m
III B
Chemor
adiation
Res CPE
Wet 
colost
omy
oment
um
Nil Nil 24
Di
ed
15 Rani
5
2
F Cervix IIB RT Rec APE
Ileal 
condu
it
Oment
um
Nil Nil 36
Lo
st 
foll
ow 
up
16 Biyula
4
3
F
Uterin
e 
sarco
ma
IV A Nil
Prima
ry
APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on
Nil 11
Ali
ve
17 Thara bai 4
5
F Cervix IIB RT Rec APE Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
Nil 36 Ali
ve
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ence
18 Anusuya
3
9
F Cervix IIIB RT
Rec
APE
Ileal 
condu
it
oment
um
Woun
d 
Infecti
on + 
perine
al 
fistula
Locor
egiona
l 
recurr
ence
42
Ali
ve
19 Kalaivani
4
0
F
Endo
metriu
m
II B RT Res MPE Nil
Oment
um
Woun
d 
Infecti
on
Nil 8
Ali
ve
20 Anjalai
3
7
F Cervix II A
Surgery 
+ RT
Rec
APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
ence
Local 
recurr
ence
18
Ali
ve
21
Dhanalak
shmi
3
5
F Cervix IIB RT Rec TPE
Wet 
colost
omy
Oment
um
Nil
Pulmo
nary 
metast
ases
14
Ali
ve
22
Chitra 
devi
4
9
F Cervix IIB RT Rec APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
ence
Nil 5
Di
ed
23 Chandra
4
5
F
Vagin
a
IV A Nil
Prima
ry
APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on
Nil 18
Ali
ve
24 Mary
4
5
F Cervix I B
Surgery 
+ RT
Rec APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on
Nil 18
Ali
ve
25 Muniam 5 F Cervix IIIB RT Res TPE Colost Oment Woun Nil 18 Ali
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mal 0
omy + 
Ileal 
condu
it
um
d 
Infecti
on
ve
26 Indira
6
3
F
Rectu
m
II A
Chemor
adiation
Rec MPE Nil
Oment
um
Woun
d 
Infecti
on
Nil 12
Ali
ve
27
Nagabho
oshanam
3
9
F Cervix IIB RT Rec TPE
Wet 
colost
omy
Oment
um
Nil Nil 4
Di
ed
28 Vanaja
5
4
F Cervix IIIB RT Res TPE
Colost
omy + 
Ileal 
condu
it
Oment
um
wound 
dehisc
ence + 
perine
al 
fistula
Nil 12
Di
ed
29
Murugay
ee
5
0
F
Urinar
y 
bladde
r
III Nil
Prima
ry
APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on
Nil 2
Di
ed
30
Saraswat
hi
4
0
F Cervix IB2 RT Res TPE
Wet 
colost
omy
Oment
um
Woun
d 
Infecti
on
Nil 7
Ali
ve
31
Bujjamm
al
5
8
F
Endo
metriu
m
IIIB RT Res APE
Ileal 
condu
it
Oment
um
Woun
d 
Infecti
on+ 
wound 
dehisc
ence
Nil 12
Ali
ve
32
Govindas
amy
7
0 M
Rectu
m IIIB
Chemor
adiation Res TPE
Wet 
colost
omy
Oment
um
wound 
dehisc
ence
Nil 6
Ali
ve
3
3
Prema
5
5 F
Vagin
a III RT Res APE
Ileal 
condu
it
Oment
um Nil Nil 7
Ali
ve
34 Rajamma 6 F Cervix IIIB RT Rec APE Ileal Oment Nil Nil 7 Ali
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l 0
condu
it
um ve
35
Kothanda
raman
6
4
M
Rectu
m
IV
Chemor
adiation
Res TPE
Wet 
colost
omy
Oment
um
Woun
d 
dehisc
ence
Nil 8
Ali
ve
36 Prema
5
5
F
Vagin
a
IV
RT
Res APE
Ileal 
condu
it
Oment
um
Woun
d 
dehisc
ence
Nil 6
Ali
ve
37
Rakeelam
mal
7
0
F
Rectu
m
III A RT Res PPE
Colost
omy
Oment
um
Nil Nil 144
Ali
ve
38
Amaravat
hi
6
2
F Ovary III C
Chemot
herapy 
+ 
Surgery
Rec MPE Nil
oment
um
Nil Nil 7
Ali
ve
39
chandrase
karan
6
1
M
Rectu
m
III B
chemor
adiation
Res TPE
Wet 
colost
omy
Oment
um
Woun
d 
infecti
on
Nil 1
Ali
ve
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